Open AccessSuppression of CMV Infection with Letermovir in a Kidney Transplant Patient
Author(s) -
Uta S Koepf,
H. U. Klehr,
Anna-M Eis-Huebinger,
Souhaib Aldabbagh,
Christian P. Strassburg,
Dominik Boes,
Philipp Lutz
Publication year - 2020
Publication title -
european journal of case reports in internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 1
ISSN - 2284-2594
DOI - 10.12890/2020_001622
Subject(s) - ganciclovir , medicine , cidofovir , cytomegalovirus , tacrolimus , cytomegalovirus infection , kidney transplantation , disease , foscarnet , drug resistance , immunology , transplantation , human cytomegalovirus , virus , herpesviridae , viral disease , biology , microbiology and biotechnology
Infection with cytomegalovirus (CMV) with resistance to ganciclovir (GCV) is a therapeutic challenge in kidney transplant patients, because standard treatment options are nephrotoxic. We report the case of a kidney transplant recipient with GCV-resistant CMV disease, in whom letermovir, a novel inhibitor of CMV packaging, was administered off-label and prevented a relapse of disease once the CMV load was decreased by cidofovir. Furthermore, we observed significant drug interactions between letermovir and tacrolimus.